A significantly higher incidence of hematologic toxicity was reported in arm B. With a median follow-up of 66 months ( range , 1 to 104 months ) , 5-year OS and event-free survival ( EFS ) rates were not significantly different between arm A and arm B , with OS being 73 % ( 95 % CI , 65 % to 81 % ) in arm A and 74 % ( 95 % CI , 66 % to 82 % ) in arm B and EFS being 64 % ( 95 % CI , 56 % to 73 % ) in arm A and 55 % ( 95 % CI , 46 % to 64 % ) in arm B.
